降压药物服药时间与心血管事件及死亡:BedMed随机临床试验
这项多中心、开放标签、实效性随机临床试验纳入3357例社区高血压成人,比较睡前与晨起服用全部每日一次降压药对主要心血管事件及死亡的影响。中位随访4.6年,睡前组主要复合终点发生率为2.3/100患者年,晨起组为2.4/100患者年(校正HR 0.96,95%CI 0.77-1.19,P=0.70),两组无显著差异,安全性结局亦无差异。
要点
- 睡前 vs 晨起服用降压药的主要复合终点发生率无显著差异(校正HR 0.96,95%CI 0.77-1.19,P=0.70)。
- 两组在全因住院/急诊就诊及跌倒、骨折、新发青光眼诊断、18个月认知下降等安全性结局上无差异。
- 作者认为降压药服药时间不影响降压治疗的获益与风险,应依据患者偏好决定。
核心结论
- 在基层医疗的高血压成人中,睡前服用降压药是安全的,但并未降低心血管风险。
- 降压药服药时间不影响降压药物的风险与获益,应依据患者偏好指导服药时间。
研究设计与样本
- 多中心、开放标签、实效性随机临床试验,采用盲法终点评估,通过5个加拿大省份的436名基层医生招募社区居住的成人高血压患者,要求至少服用1种每日一次降压药。
- 招募时间为2017年3月31日至2022年5月26日,最终随访至2023年12月22日。
- 共3357例成人按1:1随机分为睡前服药组(干预组,n=1677)和晨起服药组(对照组,n=1680)。
- 人群中56.4%为女性,中位年龄67岁,53.7%接受单药治疗,每组中位随访4.6年。
主要发现
- 主要复合终点(全因死亡或卒中、急性冠脉综合征、心力衰竭住院/急诊就诊)发生率在睡前组为2.3/100患者年,晨起组为2.4/100患者年(校正HR 0.96,95%CI 0.77-1.19,P=0.70)。
- 主要终点的各单项组分、全因住院/急诊就诊及安全性结局在两组间无差异。
- 跌倒或骨折、新发青光眼诊断及18个月认知下降在两组间无差异。
临床怎么用
- 作者认为,降压药服药时间不影响血压降低药物的风险与获益,应依据患者偏好指导服药时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Whether administration of blood pressure medications at bedtime instead of in the morning reduces cardiovascular risk is unknown, as findings from large clinical trials have not been consistent. There is also concern that bedtime antihypertensive use could induce glaucoma-related visual loss or other hypotensive/ischemic adverse effects. OBJECTIVE: To determine the effect of bedtime vs morning administration of antihypertensive medications on major cardiovascular events and death. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, pragmatic randomized clinical trial with blinded end-point assessment and recruitment via 436 primary care clinicians across 5 Canadian provinces inviting their community-dwelling adult patients with hypertension taking at least 1 once-daily antihypertensive medication. Participants were recruited from March 31, 2017, to May 26, 2022, with final follow-up on December 22, 2023. INTERVENTIONS: Participants were randomized in a 1:1 ratio to using all once-daily antihypertensive medications either at bedtime (intervention group; n = 1677) or in the morning (control group; n = 1680). MAIN OUTCOMES AND MEASURES: The primary outcome was time to first occurrence of all-cause death or hospitalization/emergency department (ED) visit for stroke, acute coronary syndrome, or heart failure. All-cause unplanned hospitalizations/ED visits, and visual, cognitive, and fall- and/or fracture-related safety outcomes were also assessed. RESULTS: A total of 3357 adults (56.4% female; median age, 67 years; 53.7% taking monotherapy) were randomized and followed up for a median of 4.6 years in each treatment group. The composite primary outcome event occurred at a rate of 2.3 per 100 patient-years in the bedtime group and 2.4 per 100 patient-years in the morning group (adjusted hazard ratio, 0.96; 95% CI, 0.77-1.19; P = .70). Individual components of the primary outcome, all-cause hospitalizations/ED visits, and safety outcomes did not differ between groups. In particular, there was no difference in falls or fractures, new glaucoma diagnoses, or 18-month cognitive decline. CONCLUSIONS AND RELEVANCE: Among adults with hypertension in primary care, bedtime administration of antihypertensive medications was safe but did not reduce cardiovascular risk. Antihypertensive medication administration time did not affect the risks and benefits of blood pressure-lowering medication and instead should be guided by patient preferences. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02990663.
引用
- Garrison SR, Bakal JA, Kolber MR, et al. Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial. JAMA. 2025. PMID: 40354045. doi:10.1001/jama.2025.4390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。